Baird raised the firm’s price target on Spyre Therapeutics (SYRE) to $90 from $65 and keeps an Outperform rating on the shares. The firm updated its model as its SPY001 UC Induction data is supportive of best-in-class potential.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics price target raised to $90 from $50 at Wells Fargo
- Spyre Therapeutics price target raised to $88 from $55 at Deutsche Bank
- Closing Bell Movers: Bloom Energy spikes on expanded Oracle deal
- Spyre Therapeutics announces $300M offering of common stock
- Spyre Therapeutics Pauses At-The-Market Equity Offering Program